Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Abhishek Kapoor Article rating: 4.0

The market opened in the green on February 5, 2020, overall volumes in futures & options currently stand at 2.29 crore contracts with a turnover of Rs. 16,47,159.52 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Abhishek Kapoor Article rating: 3.8

The market opened in the green on February 5, 2020, overall volumes in futures & options currently stand at 2.29 crore contracts with a turnover of Rs. 16,47,159.52 crore.

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

Abhishek Kapoor Article rating: 5.0

The market opened in the green on February 5, 2020. The previous trading session witnessed the Sensex going up by 917.07 points to end at 40,789.38 and the Nifty was up by 271.75 points to close at 11,979.65.

Ten stocks close to their 52-week low
Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Abhishek Kapoor Article rating: 4.4

The market opened in the green on February 5, 2020. The previous trading session witnessed the Sensex going up by 917.07 points to end at 40,789.38 and the Nifty was up by 271.75 points to close at 11,979.65.

USFDA approves Valganciclovir Hydrochloride of Granules India
USFDA approves Valganciclovir Hydrochloride of Granules India

USFDA approves Valganciclovir Hydrochloride of Granules India

Apurva Joshi Article rating: 2.7

Granules India on Wednesday said that Granules Pharmaceuticals, a wholly-owned foreign subsidiary of Granules India Limited, has received an approval from US Food & Drug Administration (USFDA) for Oral Solution 50 mg/ml of Valganciclovir Hydrochloride, which is bioequivalent to Reference Listed Drug (RLD) Valcyte for Oral Solution 50 mg/ml of Roche Palo Alto LLC.

USFDA clears Ahmedabad facility; Cadila Healthcare gains
USFDA clears Ahmedabad facility; Cadila Healthcare gains

USFDA clears Ahmedabad facility; Cadila Healthcare gains

Avalokita Pandey Article rating: 4.0

Cadila Healthcare gained 2.33 per cent today after the company informed that United States Food and Drug Administration (USFDA) has successfully completed the inspection at its manufacturing facility in Ahmedabad with no observations.

Index trend and stocks in action on February 05, 2020
Index trend and stocks in action on February 05, 2020

Index trend and stocks in action on February 05, 2020

Karan Dsij Article rating: 5.0

The Budget Day high of 12,017 is likely to act as an immediate resistance for the index. Moving past this resistance zone is likely to help bulls reclaim its 20-DMA which currently stands at 12,140. On the downside, a support is seen at the opening upside gap area (11,783-11,750). Stocks in news: Reliance Industries, Cadila Healthcare, Teamlease Services, BEML, Sun Pharmaceutical.

Bullish tone to continue today!
Bullish tone to continue today!

Bullish tone to continue today!

Karan Dsij Article rating: 5.0

With the gains posted in the last two trading sessions, markets returned to almost pre-Budget level, helped by buying across the board as nerves calmed down after the knee-jerk reaction of the Budget announcements.

Bajaj Electrical falls in PAT; Know why its still shining
Bajaj Electrical falls in PAT; Know why its still shining

Bajaj Electrical falls in PAT; Know why its still shining

Amir Shaikh Article rating: 3.0

Bajaj Electrical reported its third quarter result for the fiscal year 2019-2020 today, in which its operations revenue dipped by nearly 41 per cent YoY to Rs 1,281.5 crore in Q3FY20. The consumer durable segment reported nearly 13 per cent YoY increase in revenue.

Karda Constructions commence new project in Nashik
Karda Constructions commence new project in Nashik

Karda Constructions commence new project in Nashik

Nidhi Jani Article rating: 4.1

The total saleable area of the project shall be 1, 88,244 sq ft and expected sale proceeds should be around Rs 48.94 crore. The said project will be completed on or before December 31, 2026.

RSS
First29022903290429052907290929102911Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR